University of Kentucky

UKnowledge
Internal Medicine Faculty Publications

Internal Medicine

10-3-2012

A Phase II study of pulse dose imatinib mesylate and weekly
paclitaxel in patients aged 70 and over with advanced non-small
cell lung cancer
Julie E. Bauman
University of New Mexico

Keith D. Eaton
University of Washington

Sarah G. Wallace
University of Washington

Laurie L. Carr
National Jewish Health

Sang-Joon Lee
University of New Mexico
Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub
See next page for additional authors
Part of the Medicine and Health Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Bauman, Julie E.; Eaton, Keith D.; Wallace, Sarah G.; Carr, Laurie L.; Lee, Sang-Joon; Jones, Dennie V.;
Arias-Pulido, Hugo; Cerilli, Lisa A.; and Martins, Renato G., "A Phase II study of pulse dose imatinib
mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer"
(2012). Internal Medicine Faculty Publications. 12.
https://uknowledge.uky.edu/internalmedicine_facpub/12

This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been
accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For
more information, please contact UKnowledge@lsv.uky.edu.

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in
patients aged 70 and over with advanced non-small cell lung cancer
Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/1471-2407-12-449

Notes/Citation Information
Published in BMC Cancer, v. 12, 449.
© 2012 Bauman et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Authors
Julie E. Bauman, Keith D. Eaton, Sarah G. Wallace, Laurie L. Carr, Sang-Joon Lee, Dennie V. Jones, Hugo
Arias-Pulido, Lisa A. Cerilli, and Renato G. Martins

This article is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/12

Bauman et al. BMC Cancer 2012, 12:449
http://www.biomedcentral.com/1471-2407/12/449

RESEARCH ARTICLE

Open Access

A Phase II study of pulse dose imatinib mesylate
and weekly paclitaxel in patients aged 70 and
over with advanced non-small cell lung cancer
Julie E Bauman1,6*, Keith D Eaton2, Sarah G Wallace2, Laurie L Carr3, Sang-Joon Lee1,7, Dennie V Jones4,
Hugo Arias-Pulido1, Lisa A Cerilli5 and Renato G Martins2

Abstract
Background: In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery,
and is mediated by platelet derived growth factor receptor (PDGFR). Antagonizing PDGFR with imatinib may
improve intra-tumoral delivery of paclitaxel, increasing response rate (RR).
Methods: This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly
patients with advanced NSCLC. Eligible patients were aged ≥ 70 with untreated, stage IIIB-IV NSCLC and ECOG
performance status 0-2. Primary endpoint was RR. Secondary endpoints included median progression free and
overall survival (PFS, OS) and correlatives of PDGFR pathway activation. Baseline Charlson Comorbidity Index (CCI)
and Vulnerable Elder Survey-13 (VES-13) were correlated with outcomes.
Results: Thirty-four patients with median age 75 enrolled. Eleven of 29 (38%) were frail by VES-13 score. Overall RR
was 11/34 (32%; 95% CI 17%-51%), meeting the primary endpoint. Median PFS and OS were 3.6 and 7.3 months,
respectively. High tumoral PDGF-B expression predicted inferior PFS. Frail patients by VES-13 had significantly worse
median PFS (3.2 vs. 4.5 months; p=0.02) and OS (4.8 vs. 12 months; p=0.02) than non-frail.
Conclusions: The combination of imatinib and paclitaxel had encouraging activity as measured by the primary
endpoint of RR. However, PFS and OS were typical for elderly patients treated with single agent chemotherapy and
the regimen is not recommended for further study. Adjunct imatinib did not overcome the established association
of tumoral PDGF-B expression with inferior PFS. VES-13 was a powerful predictor of poor survival outcomes. Frailty
should be further studied as a predictor of non-benefit from chemotherapy.
Trial Registration: ClinicalTrials.gov NCT01011075
Keywords: Non-small cell lung cancer, Imatinib mesylate, Paclitaxel, Elderly, Interstitial fluid pressure,
Platelet-derived growth factor, Frailty, Vulnerable elder survey

Background
Platelet-derived growth factor receptor (PDGFR) and its
ligand, PDGF, constitute a tyrosine kinase signaling family
involved in angiogenesis, inhibition of apoptosis, and regulation of interstitial fluid pressure (IFP) [1]. PDGF is a dimeric protein with 4 isoforms, which binds to the
* Correspondence: baumanje@upmc.edu
1
Department of Internal Medicine, Divisions of Hematology/Oncology and
Biostatistics, University of New Mexico Cancer Center, Albuquerque, New
Mexico
6
University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre
Avenue, 5th floor, Pittsburgh 15232PA, USA
Full list of author information is available at the end of the article

extracellular domain of two structurally related tyrosine
kinase receptors, PDGFR-α and PDGFR-β. A classic target
of PDGF is the stromal fibroblast which expresses both α
and β receptors, predominantly β-type [2]. IFP in both
normal and malignant tissues is actively regulated by
fibroblast signaling through PDGFR-β. In solid tumors,
elevated IFP is a barrier to delivery of chemotherapy, impeding transcapillary drug transport due to Starling forces
[3]. Elevated IFP is caused by a dysfunctional stroma, featuring structurally abnormal capillaries and lymphatics,
desmoplasia, and contraction of the interstitial matrix by
fibroblasts [4]. The phenotype of interstitial hypertension
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is potentially reversible by PDGFR-β inhibition. Imatinib
mesylate (Novartis; Basel, Switzerland) is a synthetic tyrosine kinase inhibitor targeting Bcr-Abl, c-Kit and PDGFR.
In murine thyroid cancer xenografts, adjunct imatinib
decreased IFP, increased uptake of epothilone B or paclitaxel, and increased anti-tumor effects relative to chemotherapy alone [5,6]. In non-small cell lung cancer
(NSCLC) xenografts, imatinib decreased phosphorylated
PDGFR-β, vascular endothelial growth factor, and IFP
while increasing intratumoral delivery of docetaxel or liposomal doxorubicin [7].
Cytoplasmic expression of PDGF occurs in the majority
of NSCLC and is a negative prognostic indicator, while
PDGFR-β is expressed universally by tumor stroma [8-10].
Co-expression of PDGF and PDGFR-β raises the plausibility of a paracrine loop mediating interstitial hypertension
and chemotherapy resistance. Elevated IFP up to 25
mmHg has been described in lung tumors, which may
underlie low response rates to chemotherapy [11]. We
hypothesized that antagonism of PDGFR-β with imatinib
could increase the therapeutic index of weekly paclitaxel.
Paclitaxel is a mitotic inhibitor which independently
enhances perfusion and oxygenation, and decreases IFP
[12,13]. Paclitaxel is superior to best supportive care in
first line management of advanced NSCLC [14] and is
indicated in combination with platinum for fit, ageunselected patients. A taxane is an accepted single agent
standard in elderly patients with advanced NSCLC
[15,16]. Here, we report the final results from a phase II
clinical trial evaluating the combination of weekly paclitaxel and pulse dose imatinib in elderly patients with
advanced, chemotherapy-naïve NSCLC.

Methods
This multi-center study was approved by the institutional
review boards of the University of Washington-Fred
Hutchinson Cancer Research Center and the University
of New Mexico. The clinical trial was publicly registered
at ClinicalTrials.gov, NCT01011075. Key eligibility criteria included: age ≥ 70, diagnosis of advanced NSCLC
(stage IIIB with pleural effusion or IV [17]); measurable
disease according to modified RECIST criteria version 1.0
[18]; Eastern Cooperative Oncology Group performance
status (ECOG-PS) 0 to 2; adequate organ function. Key
exclusion criteria included: prior chemotherapy for
advanced NSCLC; uncontrolled brain metastases; symptomatic neuropathy (Grade ≥ 2); serious or uncontrolled
concomitant medical disorder. All patients provided
written informed consent.
Patients were treated with up to six 28-day cycles of
imatinib and paclitaxel. Paclitaxel 90 mg/m2 was administered intravenously on days 3, 10, and 17 of each 28day cycle. Imatinib 600 mg daily was administered orally
in 4-day pulses bracketing each paclitaxel infusion (days
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1-4, 8-11, 15-18), adapted from the phase I design [19].
Pulse dose imatinib was selected based upon the theoretical mechanism of action of PDGFR-β blockade,
pharmacokinetics of IFP response in xenografts, and inability to escalate paclitaxel with continuous imatinib in
phase I. The dose limiting toxicity was neutropenia, consistent with earlier reports that continuous dose imatinib
resulted in prohibitive hematologic toxicity when combined with cisplatin-irinotecan or gemcitabine [20,21].
The study incorporated a single-stage, open label,
phase II design. An interim toxicity analysis was planned
after the first 8 patients completed one cycle. The primary endpoint was response rate (RR) as measured by
modified RECIST criteria version 1.0 [18]. The assumed
null RR to single agent paclitaxel was 15%, as in CALGB
9730 [22], and a RR considered worthy of further study
was 35%. Patients inevaluable for response were considered non-responders. A sample size of 35, with 33 eligible patients had 87% power to detect a true RR of 35%,
and a 5% chance of falsely rejecting the null rate of 15%.
The decision rule rejected the null hypothesis if ≥ 9 of
33 patients responded. Secondary efficacy endpoints
included overall survival (OS), progression-free survival
(PFS), and toxicity. Survival outcomes were analyzed by
Kaplan-Meier methodology. Toxicity was described by
National Cancer Institute Common Terminology Criteria for Adverse Events, version 3 [23]. Case report
forms captured all grade ≥3 toxicities, any grade neuropathy or edema, and any grade event resulting in dose
reduction or delay.
Exploratory objectives included measurement of tumor
biomarker expression and assessment of patient comorbidity and frailty. Archived, formalin-fixed, paraffin-embedded
(FFPE) tumor specimens were collected retrospectively for
immunohistochemical (IHC) analysis. Staining for PDGF-B
(Clone N-30; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) and PDGFR-β (Clone Y92; Epitomics, Burlingame,
CA) was performed by an optimized IHC staining protocol. Normal human placental tissue previously shown to
be positive for PDGF-B and PDGFR-β was used as a
positive control; the same tissue, incubated with an
isotypic-matched antibody, was used as the negative control. Cytoplasmic PDGF-B and stromal PDGFR-β expression were graded using an H-score obtained by
multiplying staining intensity (0 negative; 1+, weak; 2+,
moderate; 3+, strong) by the percent of target cells with
positive cytoplasmic or nuclear staining (0 to 100%) [24].
The study pathologist was blinded to outcome measures.
Maximum likelihood estimates were conducted to describe the relationship of tumoral PDGF-B expression to
RR, PFS and OS. The Vulnerable Elder Survey-13 [25]
(VES-13) and Charlson Comorbidity Index [26] (CCI) respectively measured baseline frailty and comorbidity, to
explore whether such measures could predict toxicity or
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Male

23 (68%)

Female

11 (32%)

common reasons including neutropenia, neuropathy,
and fatigue. Four patients (15%) required reduction of
paclitaxel for neuropathy, elevated bilirubin, or fatigue.
Treatment-emergent grade 3 or higher adverse events
are summarized in Table 2. The most common grade ≥
3 nonhematologic toxicities were fatigue, cardiac events,
gastrointestinal events, infection, and rash. Cardiac adverse events included 2 episodes of grade 3 systolic dysfunction possibly related to imatinib, and 2 deaths from
myocardial infarction and cardiac arrest attributed to
pre-existing coronary artery disease. One death from infection and one from pneumonitis were considered
protocol-related.
Six patients were inevaluable for the primary endpoint,
due to withdrawal or death prior to first response assessment. Per predefined intent-to-treat analysis, such
patients were counted as non-responders. Eleven of 34
patients responded, with an overall RR of 32% (95% CI
17.4 – 50.5%), excluding the null rate of 15% and meeting the primary endpoint. Twelve patients had stable
disease, with an overall disease control rate of 68%. Median PFS was 3.6 months, and median OS was 7.3
months (Figure 1).
Eighteen patients submitted archived tumor for correlative studies, and 14 specimens contained viable
tumor for analysis of PDGF-B and PDGFR-β.

Adenocarcinoma

16 (47%)

Table 2 Grade ≥ 3 adverse events

Squamous

10 (29%)

Toxicity

Poorly differentiated

6 (18%)

Hematologic

Large cell/other

2 (6%)

Anemia

1 (3%)

0

0

1 (3%)

Neutropenia

4 (12%)

1 (3%)

0

5 (15%)

survival outcomes. Frailty was defined as a VES-13 score
of ≥ 3, the threshold associated with functional decline
and mortality in the ambulatory, non-oncologic geriatric
population [27]. We planned combined variable log-rank
tests to determine whether a combination of VES-13,
CCI, and/or ECOG-PS would perform better than a single variable in predicting toxicity or survival.

Results
Thirty-four patients enrolled from September 2006
through April 2010 at three participating sites, including
University of Washington, University of New Mexico
and Puget Sound Oncology Consortium. Baseline patient
characteristics are presented in Table 1. Median number
of paclitaxel cycles was 2 (range 0 – 6). Nine patients
(26%) required reduction of imatinib, with the most
Table 1 Baseline characteristics
Number (%)1

Characteristic
Age (Years)
Median

74.5

Range

70-86

Sex

Histology

2

Stage
IIIB
IV

Grade 5

Total
7 (21%)

Febrile Neutropenia

0

1 (3%)

0

26 (76%)

Thrombocytopenia

0

0

0

1 (3%)
0

Nonhematologic
Cardiac

4 (12%)

0

10 (29%)

1

18 (53%)

Systolic dysfunction

2 (6%)

0

0

2 (6%)

4 (11%)

Cardiac arrest

0

0

1 (3%)

1 (3%)

Myocardial infarction

2
Charlson Comorbidity Score (n=33)

0

1 (3%)

1 (3%)

2 (6%)

1 (3%)

0

0

1 (3%)
11 (32%)

Median

1

Edema

Range

0-7

Fatigue

10 (29%)

1 (3%)

0

Infection

3 (9%)

0

1 (3%)

4 (12%)

Constipation

2 (6%)

0

0

2 (6%)

Diarrhea

2 (6%)

0

0

2 (6%)

VES-13 Score (n=29)
Median

1

Range

0-8

VES ≥ 3 (Frail)

11 (38%)

Tumor PDGF score (n=14)
Median
Range

Gastrointestinal

4 (12%)

Pulmonary

3

3 (9%)

75

Embolism

1 (3%)

0

0

1 (3%)

0-300

Pneumonitis

0

0

1 (3%)

1 (3%)

Pneumothorax

0

1 (3%)

0

1 (3%)

2 (6%)

0

0

2 (6%)

Number(percent) unless units otherwise specified.
American Joint Committee on Cancer, 6th ed.
3
Score: Intensity of cytoplasmic staining x percent of tumor cells.
2

Grade 4

8 (24%)

ECOG Performance Status (n=32)

1

Grade 3

Bladder/Kidney stone
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Overall Survival

0.8
0.6

Probability of Survival

0.6

0.0

0.2

0.2

0.4

Median OS time=7.34 months

0.4

0.8

Median PFS time=3.56 months

0.0

Probability of Progression-Free Survival

1.0

1.0

Progression-Free Survival

0

10

20

30

40

Progression-Free Survival Time (Months)

0

10

20

30

40

Survival Time (Months)

Figure 1 Progression-Free and Overall Survival.

Representative digital photomicrographs are presented
in Figure 2. PDGF-B expression score was indirectly
associated with PFS (p=0.03), with higher tumoral expression portending earlier progression. PDGF-B score
was not associated with RR or OS. PDGFR-β was
present universally in tumor stroma with variable intensity; no membranous or cytoplasmic staining was
observed in epithelial cells. Stromal expression scores
were not associated with RR, PFS or OS.
Measures of performance status, frailty and comorbidity did not predict RR. However, frailty was significantly
associated with both PFS and OS (Figure 3). At baseline,

11 of 29 patients with available VES-13 scores met the
definition for frailty. Only 3 frail patients had an ECOGPS of 2; the remaining 8 had an ECOG-PS of 0 or 1.
Frail patients had significantly worse median PFS (3.2 vs.
4.5 months; p=0.02) and OS (4.8 vs. 12 months; p=0.02)
than non-frail. Frailty did not significantly predict toxicity. ECOG-PS was associated with OS, however not
PFS or toxicity. Patients with ECOG-PS of 0 or 1 vs. 2
had median OS of 8.3 vs. 3.2 months (p=0.04). The CCI
did not predict PFS, OS or toxicity. An exploratory,
combined variable log rank test identified the combination of VES and ECOG-PS as the best predictor of

Figure 2 PDGF-B and PDGFR-β Immunohistochemistry. Legend: Representative immunohistochemical staining of PDGF-B (A-C) and PDGFR-β
(D-F) in lung tumors (A, B, D, E) and human placenta (C, F). Inset shows the same placental tissue stained with an isotype-matched antibody.
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Overall Survival

0.8

0.8

0.4

p=0.0155

0.0

0.2

0.2

0.4

p=0.0152

0.6

VES < 3 (Median Survival Time=11.96)
VES >=3 (Median Survival Time= 4.76)

Probability of Survival

0.6

VES < 3 (Median PFS Time=4.53)
VES >=3 (Median PFS Time=3.19)

0.0

Probabilty of Progression-Free Survival

1.0

1.0
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0
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0
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Survival Time (Months)

Figure 3 Progression-Free and Overall Survival According to VES-13 Frailty Score.

differential PFS and OS. Here, good risk patients were
defined as those with VES score < 3 (non-frail) and
ECOG-PS of 0 or 1; the poor risk group included all
others. Median PFS in the good vs. poor risk group was
4.5 vs. 3.2 months (p=0.01). Similarly, median OS was
12.0 versus 4.0 months (p=0.01).

Discussion
In elderly patients with advanced NSCLC, first line treatment with the combination of intermittent, pulse dose
imatinib and weekly paclitaxel demonstrated encouraging activity as measured by the primary endpoint of
RR. As defined, the study fulfilled its primary endpoint;
however two caveats warrant discussion. First, although
RR was intriguing, both PFS and OS were numerically
similar to values seen in the elderly population treated
with single agent chemotherapy [28,29]. While the RR
indicates that pulse dose imatinib may increase early
anti-tumor effects from paclitaxel, the typical PFS and
OS suggest that enhanced efficacy is not sustained. Second, several cautionary studies have now been published
evaluating the combination of continuous dose imatinib
and a related taxane, docetaxel, in solid tumors including NSCLC [30,31], breast cancer [32], androgenindependent prostate cancer [33], and ovarian cancer
[34]. In these studies, patients were exposed to uninterrupted daily imatinib. These trials described poor tolerance; 7 of 8 were halted early for toxicity or lack of
efficacy. Specifically in NSCLC, concern was raised for
antagonism between continuous dose imatinib and docetaxel, due to a low observed RR [30].
Concurrent inhibition of PDGFR-β to overcome interstitial hypertension and improve tumoral delivery of chemotherapy has strong preclinical merit. Adjunct imatinib
significantly decreased IFP and increased drug uptake in
numerous solid tumor xenografts; efficacy measurably

increased when considering apoptosis, proliferation rate,
or tumor volume [5,6,35]. Imatinib may also serve an antiangiogenic role, as PDGF-B signaling from endothelial
cells maintains homeostasis of the pericyte. In tumor capillaries, pericytes have a structurally abnormal association
with endothelial cells resulting in excess permeability,
microaneurysms and impaired blood flow [36,37]. In
tumor models, PDGF sequestration reduced pericyte
coverage in tumor blood vessels; abnormal vessels were
selectively pruned, normalizing the vascular phenotype
[38,39]. In NSCLC xenografts, disruption of PDGF signaling similarly normalized tumor vasculature, enhancing uptake and efficacy of cyclophosphamide [40]. However, in
the same model PDGF disruption without chemotherapy
resulted in a wider perivascular sleeve of tumor cells, a
higher index of tumor proliferation, and enhanced tumor
growth. These paradoxical results caution that, while
PDGFR-β blockade may be an effective adjunct to chemotherapy, alone it may be pro-proliferative due to improved
circulatory efficiency. These preclinical findings may explain why the RR in our study stands in contrast to results
from continuous dose imatinib and docetaxel in NSCLC.
In our study, patients were exposed to 12 days of imatinib
per 28-day cycle, limiting isolated PDGFR- β inhibition. In
addition, pulse dose imatinib may have minimized proposed mechanisms of antagonism including arrest of
tumor cells at the G0-G1 checkpoint by imatinib, or
synergistic resistance mediated by each drug’s upregulation of p-glycoprotein [30]. Nonetheless, the hypothesized
normalization of IFP and tumor vasculature by pulse dose
imatinib improved only the efficiency and degree of response to paclitaxel, not the duration. Resistance to paclitaxel prevailed at the expected time point.
We hypothesized that patients with high intratumoral
PDGF-B expression, an independent negative prognostic
indicator in NSCLC [10], may differentially benefit from
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this strategy. Theoretically, tumoral production of
PDGF-B may complete two pro-survival paracrine loops:
PDGFR-β stimulation of stromal fibroblasts resulting in
contraction of the extracellular matrix and elevated IFP;
and PDGFR-β activation of neovascular pericytes. Upregulation of PDGF-B is a mechanism of chemotherapy resistance in glioma [41]. In our small sample, tumor
PDGF-B expression was not associated with RR. However, higher PDGF-B expression scores were associated
with reduced PFS. Because adjunct imatinib resulted in
similar RR in patients with high or low expression of
PDGF-B, disruption of PDGF signaling may have overcome intrinsic chemoresistance related to high IFP in
PDGF-B overexpressing tumors. However, the strategy
did not overcome the established association of high
PDGF-B expression with poor PFS. We speculate that
tumors with high PDGF-B expression may have a more
phenotypically normal vasculature, secondary to mature
pericyte coverage, limiting the anti-angiogenic benefit
from adjunct imatinib.
The combination of pulse dose imatinib and weekly
paclitaxel was adequately tolerated in this elderly cohort.
There were 2 protocol-related deaths, numerically identical to single agent paclitaxel in this population [15].
The rate of treatment-emergent Grade ≥ 3 cardiac adverse events, which occurred in 4 patients (11.8%; 95%
CI 3.3-27.5%), obligates additional discussion. This rate
is numerically higher than reported for paclitaxel monotherapy in the elderly NSCLC population (5.7%; 95% CI
0.7-19.2%), although the confidence intervals overlap
[15]. In our study, 2 patients had documented decline in
systolic function, and 2 died from myocardial infarction
in the context of pre-existing coronary artery disease, a
prevalent comorbidity associated with increasing age in
NSCLC [42]. Direct injury to the cardiomyocyte is a
recognized toxicity of imatinib, consequent to c-Abl inhibition [43]. While causality cannot be ascribed to imatinib for cardiac events in this study, there is an
established physiologic basis for potentiation of cardiac
toxicity. Caution is justified should this combination
undergo further development, particularly in patients
with pre-existing heart disease.
We conducted baseline measures of comorbidity,
frailty, and performance status, three components of
comprehensive geriatric assessment, to determine associations with treatment vulnerability and survival. Medical comorbidity, the burden of chronic disease
operationalized by the CCI, is associated with increased
surgical complications and poor survival in NSCLC
[43,44]. Frailty is the geriatric syndrome manifesting as
reduced physiologic reserve and adaptivity to environmental stress. The VES-13 frailty score predicts mortality and hospitalization in ambulatory adults [27]. In
oncology, frailty may predict treatment vulnerability
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better than chronologic age or disability [45,46]. ECOGPS, a measure of cancer-related functional impairment,
is prognostic in elderly patients with advanced NSCLC;
moreover, an ECOG-PS of 2 is a better determinant of
poor outcome than advanced age in patients receiving
single agent docetaxel [47]. In our study, VES-13 was a
powerful predictor of poor PFS and OS, and performed
better than ECOG-PS which was associated only with
OS. Moreover, VES-13 identified 8 vulnerable patients
with a favorable ECOG-PS of 0 or 1. A combined variable log rank test distinguished 2 groups with an 8
month absolute difference in OS. Specifically, non-frail
patients with ECOG-PS of 0 or 1 had a median survival
of 12 months vs. 4 months in others. Thus, assessment
of frailty with VES-13, a brief self-administered survey,
adds valuable information in the selection of elderly
NSCLC patients likely to experience survival benefit
from chemotherapy.
This study has several important limitations. First, the
absence of a randomized control group, exposed to
single-agent paclitaxel and studied with identical biomarkers, particularly limits interpretation of our PDGFB data. Second, while the majority of patients consented
to optional tissue biomarkers, only 14 samples were
analyzable, increasing the likelihood of Type II error.
Third, the standard of care for unselected elderly
patients with advanced NSCLC is evolving away from
single agent chemotherapy. At design of this study,
advanced age (>70) was a relevant selection criterion for
single agent vs. platinum doublet chemotherapy, as
addressed in national U.S. guidelines [48]. In the interval, an elderly-specific, randomized phase III trial documented superior survival from the combination of
carboplatin-paclitaxel vs. gemcitabine or vinorelbine
monotherapy [49]. Current guidelines emphasize patient
selection by performance status rather than chronologic
age [23]. Moreover, elderly patients are likely to benefit
from molecular selection by epidermal growth factor receptor and ALK gene mutations.

Conclusion
The regimen of pulse dose imatinib and weekly paclitaxel reached its primary endpoint, demonstrating an
encouraging RR in elderly patients with advanced
NSCLC. However, the benefit to adjunct imatinib was
limited to response, without an associated improvement
in PFS or OS. Reversal of elevated IFP and/or
normalization of tumor vasculature may be most beneficial early in the course of cytotoxic chemotherapy. Given
the standard of care for elderly, molecularly-unselected
NSCLC patients has evolved to platinum doublet, as well
as the significant question of cardiac toxicity, further development of this regimen does not appear justified.
Frailty, as measured by the VES-13, is a powerful
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predictor of poor survival in elderly NSCLC patients and
should be further studied as a predictor of non-benefit
from cytotoxic chemotherapy.
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